Maynard Ryan D 4
4 · RIGEL PHARMACEUTICALS INC · Filed Nov 7, 2017
Insider Transaction Report
Form 4
Maynard Ryan D
VP, CFO
Transactions
- Exercise/Conversion
Common Stock
2017-11-03$2.14/sh+100,000$214,000→ 100,000 total - Sale
Common Stock
2017-11-03$3.90/sh−100,000$390,000→ 0 total - Exercise/Conversion
Employee Stock Option (right to buy)
2017-11-03−100,000→ 75,000 totalExercise: $2.14Exp: 2025-01-26→ Common Stock (100,000 underlying)
Footnotes (2)
- [F1]The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 8, 2017.
- [F2]The option vested monthly over two years from January 1, 2015.